🔗 Share this article

A shadow economy for unapproved slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.

Investigational Drug Gaining Popularity Via Social Media

The experimental drug, which remains in clinical trials, is being promoted by online personalities for its alleged fat-burning properties. Viewers are urged to contact these accounts directly for supplier links, while also obtaining discount codes.

Active Trade on Social Networks

Additionally, a robust trade exists on Telegram, where communities with thousands of participants share “before and after” photos, administration instructions and claims of next-day British shipping. Sellers market the drug there before directing buyers to other platforms for purchases.

Understanding The Experimental Drug

This medication is an experimental injection created by US drugmaker Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist individuals lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.

Medical Experts Voice Worries

However, doctors and pharmacists have cautions that the sale of what is still an unapproved medication in the UK is a cause for concern and could result in users injecting products of uncertain source.

Some experts said the popularity for the experimental drug could be linked to the rising price of licensed slimming treatments such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed medication that must not be marketed or distributed for personal consumption under the British medical regulations.

Some influencers try to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach medicines, advertising, and customer laws, potentially leading to penalties, prosecution or imprisonment.

Platform Response and Material Elimination

Based on the social media company, the platform has removed violative content and banned related hashtags and query recommendations. The company stated it was committed to maintaining the service secure and allocating resources in strengthening enforcement strategies.

Digital Trading Operations

Investigations also found groups with up to 9,000 members marketing the experimental drug using the platform's built-in discovery tool, which functions like a public directory. Entering “retatrutide” immediately displays groups with numerous of users, filled with images of weight loss, positive reviews and step-by-step guides for mixing or injecting at home.

After minutes of joining one community, a seller shared contact information, where most purchases occur. The seller sent an guidebook and promised delivery within two days. When asked whether the product was authentic, one vendor said: “You can’t be sure.” Another shared a image of a supposed testing documentation. Not one asked about body mass, medical conditions or previous experience.

Item Information and Costs

Within these groups, posts display dark colored parcels with Royal Mail stickers, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens typically sold at 160 pounds for 20 milligrams. When asked how much time a injector should be used, sellers give contradictory responses varying between a few weeks to “depends on your body”.

Platform Moderation and Safety Actions

A representative for the messaging service said it actively monitored dangerous material on its service including content that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are injecting materials they can’t verify. Even if the research behind this drug is valid, these online products may not contain what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at Chemist4U.

A medical professional of an online medical service linked the increase in interest to recent price rises for approved weight-loss medications such as Mounjaro. “With costs increasing, patients are turning to online platforms. But counterfeit treatments are extremely risky. You can’t be certain what’s inside or whether the conditions they were made in was clean,” she explained.

Her team has previously seen individuals injured by self-injection from unconfirmed suppliers. “We recognize the frustration, but buying from Telegram or WhatsApp is gambling with your health,” stated the doctor. “These substances could be impure or improperly measured.”

Manufacturer Position

A representative from Eli Lilly said retatrutide was in third stage clinical trials and had not been evaluated or approved by any government authority globally. “Therefore at this point no one can market [it] for human use,” they said, noting that any item “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may expose patients to potentially significant health risks”.